Month: September 2020

STORM Therapeutics Logo

FutureNeuro partners with STORM Therapeutics to explore the role of RNA epigenetics in epilepsy.

Dublin, Ireland.  9 September 2020.  FutureNeuro has announced that it has entered into partnership with Seroba’s portfolio company, STORM Therapeutics, the leading biotechnology company focused on the discovery and development of small molecule therapies modulating RNA epigenetics, to explore new treatment options for people with epilepsy. The project, which will be led by Dr. Gary …

FutureNeuro partners with STORM Therapeutics to explore the role of RNA epigenetics in epilepsy. Read More »

Pq Bypass

PQ Bypass Receives FDA “Breakthrough Device Designation” for the World’s First Fully Percutaneous Femoral-Popliteal Bypass Device.

MILPITAS, Calif. – September 2, 2020 – PQ Bypass Inc, a medical device pioneer bringing new advancements to the treatment of advanced peripheral artery disease (PAD), announced today that they received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA) for the Detour System. The Detour System is the world’s first fully-percutaneous femoral-popliteal …

PQ Bypass Receives FDA “Breakthrough Device Designation” for the World’s First Fully Percutaneous Femoral-Popliteal Bypass Device. Read More »

T: 353 (0)1 633 4028

18 Herbert Street
Dublin 2
D02 FK19
Ireland

Scroll to Top